

# Hanna Gyllensten

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/904707/publications.pdf>

Version: 2024-02-01

49  
papers

967  
citations

516710

16  
h-index

477307

29  
g-index

51  
all docs

51  
docs citations

51  
times ranked

1393  
citing authors

#	ARTICLE	IF	CITATIONS
1	Commentary: how person-centred is pharmaceutical care?. International Journal of Clinical Pharmacy, 2022, 44, 270-275.	2.1	7
2	Implementation fidelity of a transition program for adolescents with congenital heart disease: the STEPSTONES project. BMC Health Services Research, 2022, 22, 153.	2.2	4
3	A Lifestyle Intervention During Pregnancy and Its Effects on Child Weight 2.5 Years Later. Maternal and Child Health Journal, 2022, , 1.	1.5	0
4	Effects of a Person-Centered eHealth Intervention for Patients on Sick Leave Due to Common Mental Disorders (PROMISE Study): Open Randomized Controlled Trial. JMIR Mental Health, 2022, 9, e30966.	3.3	6
5	Early vs. late treatment initiation in multiple sclerosis and its impact on cost of illness: A register-based prospective cohort study in Sweden. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732210924.	1.0	2
6	Room4Birth – The effect of giving birth in a hospital birthing room designed with person-centred considerations: A Swedish randomised controlled trial. Sexual and Reproductive Healthcare, 2022, 32, 100731.	1.2	9
7	Mechanisms of impact and experiences of a person-centred transition programme for adolescents with CHD: the Stepstones project. BMC Health Services Research, 2021, 21, 573.	2.2	14
8	Systematic review of the healthcare cost of bronchopulmonary dysplasia. BMJ Open, 2021, 11, e045729.	1.9	12
9	Cost effectiveness of a controlled lifestyle intervention for pregnant women with obesity. BMC Pregnancy and Childbirth, 2021, 21, 639.	2.4	3
10	Effects of Person-Centered Care Using a Digital Platform and Structured Telephone Support for People With Chronic Obstructive Pulmonary Disease and Chronic Heart Failure: Randomized Controlled Trial. Journal of Medical Internet Research, 2021, 23, e26794.	4.3	13
11	Healthcare, Sickness Absence, and Disability Pension Cost Trajectories in the First 5 Years After Diagnosis with Multiple Sclerosis: A Prospective Register-Based Cohort Study in Sweden. PharmacoEconomics - Open, 2020, 4, 91-103.	1.8	13
12	A national research centre for the evaluation and implementation of person-centred care: Content from the first interventional studies. Health Expectations, 2020, 23, 1362-1375.	2.6	21
13	Importance of early treatment decisions on future income of multiple sclerosis patients. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732095911.	1.0	6
14	Person-centred care by a combined digital platform and structured telephone support for people with chronic obstructive pulmonary disease and/or chronic heart failure: study protocol for the PROTECT randomised controlled trial. BMJ Open, 2020, 10, e036356.	1.9	11
15	Modelling the cost-effectiveness of person-centred care for patients with acute coronary syndrome. European Journal of Health Economics, 2020, 21, 1317-1327.	2.8	7
16	Person-centred eHealth intervention for patients on sick leave due to common mental disorders: study protocol of a randomised controlled trial and process evaluation (PROMISE). BMJ Open, 2020, 10, e037515.	1.9	7
17	Factors affecting adolescents' participation in randomized controlled trials evaluating the effectiveness of healthcare interventions: the case of the STEPSTONES project. BMC Medical Research Methodology, 2020, 20, 205.	3.1	11
18	The cost-effectiveness of person-centred care provided to patients with chronic heart failure and/or chronic obstructive pulmonary disease. Health Policy OPEN, 2020, 1, 100005.	1.5	15

#	ARTICLE	IF	CITATIONS
19	Costs of illness progression for different multiple sclerosis phenotypes: a population-based study in Sweden. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731985838.	1.0	11
20	Clinical relevance of alerts from a decision support system, PHARAO, for drug safety assessment in the older adults. <i>BMC Geriatrics</i> , 2019, 19, 164.	2.7	8
21	Person-Centred Care in Patients with Acute Coronary Syndrome: Cost-Effectiveness Analysis Alongside a Randomised Controlled Trial. <i>PharmacoEconomics - Open</i> , 2019, 3, 495-504.	1.8	23
22	Cohort study of healthcare use, costs and diagnoses from onset to 6 months after discharge for takotsubo syndrome in Sweden. <i>BMJ Open</i> , 2019, 9, e027814.	1.9	6
23	Transition program for adolescents with congenital heart disease in transition to adulthood: protocol for a mixed-method process evaluation study (the STEPSTONES project). <i>BMJ Open</i> , 2019, 9, e028229.	1.9	18
24	Room4Birth - the effect of an adaptable birthing room on labour and birth outcomes for nulliparous women at term with spontaneous labour start: study protocol for a randomised controlled superiority trial in Sweden. <i>Trials</i> , 2019, 20, 629.	1.6	12
25	Trajectories of sickness absence and disability pension before and after opioid initiation for noncancer pain: a 10-year population-based study. <i>Pain</i> , 2019, 160, 1224-1233.	4.2	10
26	Economic evaluation of a person-centred care intervention in head and neck oncology: results from a randomized controlled trial. <i>Supportive Care in Cancer</i> , 2019, 27, 1825-1834.	2.2	13
27	Cognitive function is a major determinant of income among multiple sclerosis patients in Sweden acting independently from physical disability. <i>Multiple Sclerosis Journal</i> , 2019, 25, 104-112.	3.0	37
28	Costs of illness of multiple sclerosis in Sweden: a population-based register study of people of working age. <i>European Journal of Health Economics</i> , 2018, 19, 435-446.	2.8	29
29	Comparing costs of illness of multiple sclerosis in three different years: A population-based study. <i>Multiple Sclerosis Journal</i> , 2018, 24, 520-528.	3.0	16
30	Increasing return-to-work among people on sick leave due to common mental disorders: design of a cluster-randomized controlled trial of a problem-solving intervention versus care-as-usual conducted in the Swedish primary health care system (PROSA). <i>BMC Public Health</i> , 2018, 18, 889.	2.9	18
31	Mighty Mums – a lifestyle intervention at primary care level reduces gestational weight gain in women with obesity. <i>BMC Obesity</i> , 2018, 5, 16.	3.1	15
32	Disposable income trajectories of working-aged individuals with diagnosed multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2018, 138, 490-499.	2.1	4
33	Costs and quality of life by disability among people with multiple sclerosis: a register-based study in Sweden. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018, 4, 205521731878335.	1.0	12
34	Comparing Methods for Estimating Direct Costs of Adverse Drug Events. <i>Value in Health</i> , 2017, 20, 1299-1310.	0.3	6
35	Direct and indirect costs for adverse drug events identified in medical records across care levels, and their distribution among payers. <i>Research in Social and Administrative Pharmacy</i> , 2017, 13, 1151-1158.	3.0	4
36	Income in Multiple Sclerosis Patients with Different Disease Phenotypes. <i>PLoS ONE</i> , 2017, 12, e0169460.	2.5	13

#	ARTICLE	IF	CITATIONS
37	Cost of Illness of Multiple Sclerosis - A Systematic Review. PLoS ONE, 2016, 11, e0159129.	2.5	131
38	Effectiveness of person-centred care after acute coronary syndrome in relation to educational level: Subgroup analysis of a two-armed randomised controlled trial. International Journal of Cardiology, 2016, 221, 957-962.	1.7	41
39	How does work disability of patients with MS develop before and after diagnosis? A nationwide cohort study with a reference group. BMJ Open, 2016, 6, e012731.	1.9	21
40	Earnings and Financial Compensation from Social Security Systems Correlate Strongly with Disability for Multiple Sclerosis Patients. PLoS ONE, 2015, 10, e0145435.	2.5	32
41	Pharmacoepidemiology at Nordic School of Public Health NHV: Examples from 1999 to 2014. Scandinavian Journal of Public Health, 2015, 43, 73-80.	2.3	1
42	Potentially inappropriate prescribing and adverse drug reactions in the elderly: a population-based study. European Journal of Clinical Pharmacology, 2015, 71, 1525-1533.	1.9	104
43	Adherence to Antihypertensive Therapy and Elevated Blood Pressure: Should We Consider the Use of Multiple Medications?. PLoS ONE, 2015, 10, e0137451.	2.5	45
44	Economic Impact of Adverse Drug Events – A Retrospective Population-Based Cohort Study of 4970 Adults. PLoS ONE, 2014, 9, e92061.	2.5	50
45	Prevalence, nature and potential preventability of adverse drug events – a population-based medical record study of 4970 adults. British Journal of Clinical Pharmacology, 2014, 78, 170-183.	2.4	58
46	Cost of illness of patient-reported adverse drug events: a population-based cross-sectional survey. BMJ Open, 2013, 3, e002574.	1.9	38
47	How are the Costs of Drug-Related Morbidity Measured?. Drug Safety, 2012, 35, 1.	3.2	14
48	Modelling drug-related morbidity in Sweden using an expert panel of physicians. European Journal of Clinical Pharmacology, 2012, 68, 1309-1319.	1.9	6
49	Modelling drug-related morbidity in Sweden using an expert panel of pharmacists™. International Journal of Clinical Pharmacy, 2012, 34, 538-546.	2.1	10